Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a ran
- PDF / 605,357 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 77 Downloads / 176 Views
ORIGINAL INVESTIGATION
Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial Benjamín Vicente 1
&
Sandra Saldivia 1 & Naín Hormazabal 2 & Claudio Bustos 1 & Patricia Rubí 1
Received: 3 June 2019 / Accepted: 21 July 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Objective To determine whether etifoxine, a non-benzodiazepine drug of the benzoxazine family, is non-inferior compared with clonazepam in the treatment of anxiety disorders. Method A randomized controlled double blind trial with parallel groups was conducted. A total of 179 volunteer patients with a diagnosis of anxiety disorder (DSM-IV), between 18 and 64 years of age, participated in this study. The experimental group received 150 mg/day of etifoxine and the control 1 mg/day of clonazepam, both in three daily doses for 12 weeks. This treatment was completed by 87 participants, and 70 were available for follow-up at 24 weeks from start of treatment. The primary objective was a non-inferiority comparison between etifoxine and clonazepam in the decrease of anxiety symptoms (HAM-A) at 12 weeks of treatment. Secondary outcomes included the evaluation of medication side effects (UKU), anxiety symptoms at 24 weeks of treatment, and clinical improvement (CGI). Data analysis included multiple imputation of missing data. The effect of etifoxine on the HAM-A, UKU, and CGI was evaluated with the intention of treatment, and a sensitivity analysis of the results was conducted. Non-inferiority would be declared by a standardized mean difference (SMD) between clonazepam and etifoxine not superior to 0.31 in favour of clonazepam. Results Using imputed data, etifoxine shows non-inferiority to clonazepam on the reduction of anxiety symptoms at the 12-week (SMD = 0.407; 95% CI, 0.069, 0.746) and 24-week follow-ups (SMD = 0.484; 95% CI, 0.163, 0.806) and presented fewer side effects (SMD = 0.58; 95% CI, 0.287, 0.889). LOCF analysis shows that etifoxine is non-inferior to clonazepam on reduction of anxiety symptoms and adverse symptoms even when no change was assigned as result to participant whom withdrew. Noninferiority could be declared for clinical improvement (SMD = 0.326; 95% CI, − 0.20, 0.858). Conclusion Etifoxine was non-inferior to clonazepam on reduction of anxiety symptoms, adverse effects, and clinical improvement. Keywords Anxiety . Etifoxine . Clonazepam . Benzodiazepines . Non-inferiority trial
* Benjamín Vicente [email protected] Sandra Saldivia [email protected] Naín Hormazabal [email protected] Claudio Bustos [email protected] Patricia Rubí [email protected] 1
Department of Psychiatry and Mental Health, Universidad de Concepción, Av. Juan Bosco s/n, Casilla 160-C, Concepción, Chile
2
Ñuble Health Service, Bulnes 502, Chillán, Chile
Introduction Anxiety disorders have, as the main symptom, the presence of excessive fear and anxiety, associated with behavioural alterations that can generate malaise and disability (
Data Loading...
